Naphazoline
As of the edition of 20 October 2026, Naphazoline is a small molecule: marketed, first approved in 1953 (ES); acts on ADRA1A, ADRA1B and ADRA1D and 3 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1994
- Kind
- Small molecule
- Brand name
- Naphcon-A
- First approved
- 1 September 1953 (ES)
- Approvals on record
- 9 in 4 regions
- Holder of the most recent approval
- Johnson & Johnson; 7 holders in all
- Registered trials
- 7, 0 stopped early
- Disease areas
- Eye; Immune system; Cancer; Infections; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Naphazoline.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 3 | 3 | 3 | 0 | 0 |
| Phase 4 | 2 | 1 | 0 | 0 |
| All trials | 7 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Alcon | Applicant | 1980 to now |
| Bausch Health | Later holder and Lead sponsor of trials | 1987 to now |
| Johnson & Johnson | Later holder | 2001 to now |